Viewing nowCombinationSitaren Duo Tablet 50/500 mg
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Nexpharm Korea Co., Ltd.

MFDS item code 202200032 · Approved 2022.01.03 · Insurance code 662504710
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used to effectively control blood glucose levels in patients with type 2 diabetes. It can be administered alone to patients starting drug treatment for the first time, and can also be used as an alternative therapy when monotherapy with metformin or sitagliptin is insufficient. Additionally, if blood glucose control is difficult in patients already on combination therapy with metformin and sulfonylurea, thiazolidinedione, or insulin, this medication can be used in combination to enhance therapeutic effects. This medication assists with dietary and exercise therapy and helps improve blood glucose control.
In antidiabetic therapy, the dose of this medication should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medication is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this medication should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior antidiabetic drug treatment whose blood glucose is not adequately controlled with monotherapy, or for whom adequate blood glucose control cannot be achieved with sitagliptin monotherapy, the initial dose is 1 tablet of this medication 50/500 mg twice daily. The dose may be increased to 1 tablet of this medication 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medication (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended initial dose is sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medication may start at their current doses of sitagliptin and metformin. 3. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medication. Any change in the treatment regimen for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medication because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medication should be discontinued immediately. Patients with hepatic impairment This medication should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).
This medication contains sitagliptin and metformin and is used in the treatment of diabetes. When taking this medication, severe allergic reactions may occur, so if symptoms such as skin rash, urticaria, difficulty breathing, or swelling of the face or neck appear, you should stop taking it immediately and inform a doctor. Serious pancreatic inflammation known as pancreatitis may occur, so immediate consultation with healthcare providers is necessary if symptoms such as abdominal pain, nausea, vomiting, or fever occur. Patients with severely impaired kidney function, acute illnesses, heart failure, myocardial infarction, sepsis, or those with similar conditions should not use this medication. Administration should be temporarily suspended before and after examinations using iodine contrast agents, and should only be resumed after confirming normal kidney function. Pregnant women, women who may become pregnant, and nursing mothers should not use this medication. Exercise caution if experiencing irregular meals, nutritional deficiencies, or intense physical activity as this may increase the risk of hypoglycemia and lactic acidosis. Regular kidney function tests must be done during treatment, and if any abnormal symptoms occur, you should consult a healthcare provider immediately. Additionally, consumption of alcohol should be avoided as it may increase the risk of lactic acidosis. This medication may increase the risk of hypoglycemia when taken together with other glucose-lowering agents, particularly insulin or sulfonylurea, so dosage adjustments may be necessary. It is advised to discontinue this medication at least 48 hours before surgery, and resumption should occur only after normal oral intake is restored and kidney function is confirmed. While taking this medication, regular blood glucose monitoring and liver, kidney function, and blood tests should be carried out to monitor for adverse reactions. Rarely, severe joint pain, skin conditions, and muscle pain may occur, so consultation with a physician is necessary if symptoms appear. In case of overdose, visit a hospital immediately for appropriate treatment; blood dialysis may be beneficial.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air exposure, and kept at room temperature between 1 degree and 30 degrees Celsius. Storing it this way helps maintain the medication's effectiveness over time.
Bright pink oval film-coated tablets
30 tablets/box [(10 tablets/PTP x 3)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Nexpharm Korea Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Eden Pharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.